SCHEMBL14770511

SCHEMBL14770511

COc1ccc(C(O)c2nc3cc(Cl)cnc3[nH]2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
MLKL Q8NB16 2/20 0.43
CHEK2 O96017 1/20 0.40
MTNR1B P49286 3/20 0.39
MTNR1A P48039 2/20 0.39
MAPK1 P28482 2/20 0.38
GAA P10253 2/20 0.38
TSHR P16473 1/20 0.38
ALDH1A1 P00352 1/20 0.36
ATM Q13315 1/20 0.36
AOC3 Q16853 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
CCNB2 O95067 1/20 0.36
CDK1 P06493 1/20 0.36
CCNB1 P14635 1/20 0.36
GSK3A P49840 1/20 0.36
GSK3B P49841 1/20 0.36
CDK5 Q00535 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14770519 0.86 MAPK1 (0.38) MEN1KMT2AMAPK1CCNB2CDK1
SCHEMBL14770724 0.85 MEN1 (0.41) MEN1KMT2AMLKLCHEK2MTNR1B
SCHEMBL14770725 0.85 MEN1 (0.39) MEN1KMT2AMLKLCHEK2MAPK1
SCHEMBL12065251 0.85 MLKL (0.38) MEN1KMT2AMLKLMAPT
SCHEMBL14770697 0.82 MLKL (0.51) MEN1KMT2AMLKLCHEK2MTNR1B
SCHEMBL14770516 0.79 GAA (0.46) MLKLCHEK2MAPK1GAATSHR
SCHEMBL14770513 0.79 MLKL (0.43) MEN1KMT2AMLKLCHEK2MTNR1B
SCHEMBL14770517 0.77 ALDH1A1 (0.38) MEN1KMT2ACHEK2GAAALDH1A1
SCHEMBL14770690 0.77 MLKL (0.52) MEN1KMT2AMLKLCHEK2MTNR1B
SCHEMBL14770661 0.74 MLKL (0.72) MEN1KMT2AMLKLMAPK1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 US disclosed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE CACNA1E, CACNA1G, CACNA1A MEN1 2676/4885KMT2A 4545/4885MLKL 2378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.